Mainstream

Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model

Royalty Pharma raises 2025 portfolio receipts guidance to $3.05B-$3.15B as integrated company advances biotech funding model

Post ContentrprxRead More

You might also be interested in reading UK consumers plan to ‘buy British’ as Trump’s trade war bites.

August 6, 2025
In Mainstream